Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

DWS Group GmbH & Co KGaA reports robust financial performance with significant net inflows and strategic initiatives, despite challenges in active equity strategies and market volatility.

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Quarter Results/ForecastDrägerwerk AG & Co. KGaA: Dräger with strong demand in the first quarter of 2025 30.04.2025 / 07:30 CET/CESTThe issuer is solely responsible for the content of this ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

Recent developments in health highlight key agreements between countries, drug approvals, corporate revenue growth, and ...

ESG/SustainabilityAsklepios Group: Publication of Asklepios CSRD Report 2024 30.04.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Asklepios Group: ...

The FDA and other HHS agencies of interest to the pharma sphere have seen President Donald Trump’s first 100 days as he ...

We are pleased to share the April 2025 issue of Wilson Sonsini's Sustainability and ESG Advisory Practice Update. Each issue combines news, key ...